Novartis India Share Price

Novartis India Share Price

NSE: NOVARTIND
|
Trading
|
S Cap
₹ 1,646.70
+₹32.60 (2.02%)
1D
Last updated 04 Sep, 2026, 15:29 IST

Novartis India Share Price Today

As of 5 Sep 2026, Novartis India share price is ₹1,646.70. The stock opened at ₹1,614.90, compared to its previous close of ₹1,614.10. During today's trading session, Novartis India share price moved in the range of ₹1,614.90 to ₹1,665.00, with an average price of ₹1,639.95 for the day. Looking at its last 52-week, the stock has touched a low of ₹950.00 and a high of ₹1,780.00. On the performance front, Novartis India share price has increased by 65.42% over the last six months and is up 65.42% on a year-on-year basis.

₹1,614.90
2.02% up today
₹1,665.00
1D LOW
1D HIGH

Novartis India Returns Calculator

Circuit
L
H
₹1,291.30
₹1,936.90
52-week
L
H
₹950.00
₹1,780.00

About Novartis India

Novartis India Share Price
ISIN
INE234A01025
Sector Market Cap
₹ 3,987.44 Cr

Novartis India Limited is an India-based company. The Company is primarily engaged in the business of trading of Pharmaceuticals. It operates in the Pharmaceutical business segment. The Company’s brands hold key positions in therapeutic areas, such as, Voveran, which is the brand for bone and pain; Simulect, Certican, Sandimmun, Neoral, and Myfortic, which is the brand for transplantation immunology; and Tegrital and Exelon, which is the brand for neurosciences.

Novartis India Financial Highlights

  • Revenue: Novartis India reported revenue of ₹393.10 crore in FY26 vs ₹398.23 crore in FY25. It showed a decrease of 1.29% on a yearly basis.
  • Operating Profit: Novartis India reported an operating profit of ₹129.66 crore in FY26 vs ₹130.42 crore in FY25. It showed a decrease of 0.58% on a year-on-year basis.
  • Net Profit: Novartis India reported a net profit of ₹93.18 crore in FY26 vs ₹100.90 crore in FY25. It showed a decrease of 7.65% on a yearly basis.

Novartis India Quarterly Result Highlights

  • Novartis India reported revenue of ₹112.55 crore in Jun 2026, compared with ₹100.56 crore in Mar 2026, representing an increase of 11.92% on a quarter-on-quarter (QoQ) basis.
  • Novartis India reported an operating profit of ₹43.17 crore in Jun 2026, compared with ₹30.14 crore in Mar 2026, representing an increase of 43.23% on a quarter-on-quarter (QoQ) basis.
  • Novartis India reported a profit of ₹32.21 crore in Jun 2026, compared with ₹25.25 crore in Mar 2026, reflecting an increase of 27.56% on a QoQ basis.
  • The earnings per share (EPS) of Novartis India stood at ₹40.87 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
70.68%
FII
0.15%
Other DII
0.66%
Retail and other
27.78%
Mutual funds
0.72%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20250.19%
Mar 20260.17%
Jun 20260.16%
Jul 20260.15%
Mkt Cap Cr
3,987.44
P/E
40.78
P/B
4.88
ROE
11.39%
D/E
0.00
ROCE
15.94%
Div. Yield
0.00%
EPS(TTM)
37.74
Turnover
0.38
EV/EBITDA
23.72
Net Margin
0.00%
Op. Margin
0.00%
ROA
9.99%
Quick Ratio
0.00
Curr. Ratio
5.36
Based on fundamentals, this stock's
Step 4 of 5
Performance
Good
Novartis India outperforming most market indices
Step 1 of 5
Valuation
Overvalued
Novartis India appears overvalued compared to its peers
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,56,833.0037.705.4713.74%0.6117.33%93.240.84%0.4810.90
Divis Laboratories2,45,426.0083.9114.6415.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,87,320.0086.8922.2825.49%1.6913.85%222.760.69%0.4958.70
Zydus Lifesciences1,13,217.0024.654.1818.59%0.3117.35%237.300.09%0.3335.38
Cipla1,12,212.0033.443.2611.27%0.0014.95%423.360.94%0.4543.52
Laurus Labs1,01,155.0092.7719.0916.77%0.4016.14%97.200.11%0.6713.72
Lupin97,626.3017.594.3523.76%0.0424.88%659.000.84%0.57129.18
Mankind Pharma96,859.1046.845.9411.74%0.3413.13%396.980.04%0.4449.37
Dr. Reddy's Laboratories96,405.5030.282.5311.07%0.1812.54%377.950.69%0.4138.68
Aurobindo Pharma93,614.0025.232.479.25%0.1911.76%394.820.25%0.3841.58

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Novartis India Financials

Full statement

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Revenue₹356.27₹335.07₹378.74₹399.87
Other Income₹41.96₹61.68₹58.11₹33.19
Total Revenue₹398.23₹396.75₹436.85₹433.06
Total Expenses₹267.81₹273.91₹321.47₹387.24
Profit Before Tax₹130.42₹122.84₹115.38-₹3.82
Tax₹29.52₹37.65₹12.02-₹0.10
Profit After Tax₹100.90₹85.19₹103.36-₹3.72
EPS - Basic₹40.87₹34.50₹41.86-₹1.51
EPS - Diluted₹40.87₹34.50₹41.86-₹1.51

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹129.66₹130.42₹122.84₹115.38
Income before WC changes₹95.90₹91.62₹66.09₹66.46
Change in Assets-₹11.08₹18.66₹21.49₹23.43
Change in Liabilities-₹2.83-₹19.42-₹12.45-₹47.43
Change in WC-₹13.91-₹0.76₹9.04-₹24.00
Cash flow from Operations₹46.73₹74.57₹113.40₹44.80
Cash flow from Investing₹17.63-₹3.31₹33.13-₹153.25
Cash flow from Financing-₹63.93-₹64.15-₹120.99-₹30.48
Total Cash Flow₹0.43₹7.11₹25.54-₹138.93
Cash (Start of the year)₹52.07₹44.96₹19.42₹158.35
Cash (End of the year)₹52.50₹52.07₹44.96₹19.42

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2025Mar 2024Mar 2023Mar 2022
Non-Current Assets₹201.99₹225.67₹305.61₹248.84
Current Assets₹745.82₹699.26₹677.33₹708.73
Total Assets₹947.81₹924.93₹982.94₹957.57
Current Liabilities₹142.05₹157.20₹159.49₹216.42
Net Current Asset₹603.77₹542.06₹517.84₹492.31
Non-Current Liabilities₹20.80₹22.91₹47.79₹49.45
Equity Capital₹784.96₹744.82₹775.66₹691.70
Total Equity & Liabilities₹947.81₹924.93₹982.94₹957.57
* All values are in INR Crore
Qty
Bid
4
1646.7
0
0
0
0
0
0
0
0
Ask
Qty
0
0
0
0
0
0
0
0
0
0
Bid Total: 4
Ask Total: 0
Buy orders: 100%
Sell orders: 0%
Bearish
4
Neutral
3
Bullish
1
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
62.71
Neutral
ATR (14)
62.66
Neutral
STOCH(9,6)
94.11
Bearish
STOCH RSI (14)
100
Bearish
ADX(9)
25.66
Bearish
UO(9)
59.65
Neutral
ROC(12)
7.92
Bullish
WillR(14)
-4.56
Bearish
Period
Simple value
Exponential vaue
5D
1567.68
1576.26
10D
1522.61
1554.5
20D
1547.94
1551.32
50D
1555.12
1544.31
100D
1408.87
0
Volume trend — traded volume by day
4 Sep0L
3 Sep0L
2 Sep0L
1 Sep0L
31 Aug0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
Novartis India Share Price
Novartis India
Trading
Add Stock
Add Another

Novartis India Share Price FAQs

Novartis India share price data is sourced from NSE/BSE and may be delayed. It is displayed for informational purposes only and does not constitute investment advice or a recommendation to buy or sell.

Trusted by 2 Crore+ Indians for their wealth-building needs. SEBI Registered Broker. SEBI Reg No. INZ000315837